Failing Alzheimer’s Test?

Two new studies claim that a shoddy test may have caused Alzheimer’s drugs to fail in clinical trials.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Flickr, kevin dooleyAfter several drugs promising to slow or even reverse the cognitive decline of Alzheimer’s disease flopped in clinical trials the past few years, two new studies suggest that one of the standard tests to measure cognitive performance may have been the common stumbling block. The new studies, both published in Alzheimer's & Dementia yesterday (Decebmer 18), provide evidence that the Alzheimer’s Disease Assessment Scale—Cognitive Behavior section (ADAS-Cog) may not be sensitive enough to detect minor improvements, but other researchers are skeptical that the ADAS-Cog was the downfall of previous trials.

“The negative results are due to the small effect size of the drug being tested and not the measurement instrument,” Stephen Salloway, director of neurology and the Memory and Aging Program at Butler Hospital in Providence, Rhode Island, told Nature. “I wish I could blame it on the test.”

The ADAS-Cog test—which scores patients in 11 areas, such as memory and language—was developed in 1984, when scientists and clinicians’ understanding of Alzheimer’s was more limited. In the new studies, researchers led by Jeremy Hobart, a neurologist at the Plymouth University Peninsula Schools of Medicine and Dentistry in the United Kingdom, found that the test wasn’t able to distinguish fine changes in patients in the early stages of disease. Moreover, Hobart and colleagues used a mathematical ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Beth Marie Mole

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio 
Zymo Research

Zymo Research Launches Microbiome Grant to Support Innovation in Microbial Sciences